AXIM Biotechnologies, Inc. Stock price Other OTC
Equities
AXIM
US05463V1008
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | 60.46K | Sales 2022 | 8.88K | Capitalization | 5.16M |
---|---|---|---|---|---|
Net income 2021 | -16M | Net income 2022 | -6M | EV / Sales 2021 | 1,092 x |
Net Debt 2021 | 6.3M | Net Debt 2022 | 5.64M | EV / Sales 2022 | 1,218 x |
P/E ratio 2021 |
-3.55
x | P/E ratio 2022 |
-0.69
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 66.74% |
Managers | Title | Age | Since |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 16-06-28 |
Kurt Phinney
COO | Chief Operating Officer | - | 23-05-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 17-05-17 |
Director/Board Member | 76 | 17-05-17 |
1st Jan change | Capi. | |
---|---|---|
+9.16% | 45.97B | |
+53.35% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |